Navinta III Inc Email Formats

About Navinta III Inc

Navinta III, a dynamic generic pharmaceutical company founded in 2016, is committed to transforming innovative ideas into breakthrough medicines for chronic and life-threatening diseases. Embracing its name's essence, "novelty," Navinta focuses on revolutionizing pharmaceutical development and advancing innovation to the market with new medicinal solutions. With an impressive portfolio of 21 process and product patents, 29 active Drug Master Files, and 15 approved ANDA products, Navinta leads in developing new formulations, complex products, and pioneering delivery systems. Our team of world-class scientists is advancing a diverse pipeline featuring analgesics, cardiovascular agents, cytotoxic anticancer compounds, innovative delivery sprays, and uniquely formulated oral dosage forms. These products are strategically advanced through traditional ANDA filings, NDA submissions, and device applications. Beyond dosage forms, our chemical process group innovates in cytotoxic, sterile, and liquid APIs, alongside the cGMP manufacturing of controlled substances at our DEA-registered facility. Navinta's robust global supply chain collaborates with FDA and MHRA-approved contract manufacturing organizations to produce and serialize products for global distribution. Our unwavering commitment to quality is reflected in our Quality Assurance efforts, continuous improvement programs, and rigorous supplier performance management, ensuring top-tier product standards at competitive costs. We operate with a profound commitment to accountability and integrity, valuing our patients, customers, communities, and business partners.

View contact profiles from Navinta III Inc